Abstract
Current cancer gene therapies rely primarily on antitumor immunity, but the exploration of alternative mRNA cargoes for direct antitumor effects is crucial to expand cancer gene therapies. Here we show that lipid nanoparticles (LNPs) carrying mRNA encoding a viral 3C protease can efficiently suppress tumors by selectively inducing tumor cell apoptosis. In various solid tumor models, intracranial injection of LNPs carrying mRNA encoding the 3C protease (3C-LNPs) significantly inhibits tumor growth and prolongs survival in glioblastoma models. Similarly, subcutaneous injection reduces tumor volume and inhibits angiogenesis in a breast cancer model, while intravenous injection inhibits tumor growth and angiogenesis and prolongs survival in hepatocellular carcinoma models. Mass spectrometry and cleavage site prediction assays identify heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) as the main target degraded by the 3C protease. This study suggests that viral protease mRNA could be a promising broad-spectrum antitumor therapeutic.
Introduction
Most current mRNA-based cancer therapies are "indirect": they act as vaccines to train the immune system or encode cytokines to stir up an immune response. While promising, these approaches often struggle with patients who have weakened immune systems or tumors that have "cloaked" themselves from immune detection. Furthermore, complex treatments like CAR-T cell therapy are expensive and time-consuming to produce.
The authors sought a direct tumoricidal strategy—a way to kill cancer cells regardless of the patient's immune status. They looked to nature’s own specialists in cell hijacking: viruses. Specifically, they focused on the 3C protease from Enterovirus 71 (EV71), a viral enzyme that acts like molecular scissors to cut up host cell proteins.
Methods and Validation
The team designed an mRNA sequence encoding the EV71 3C protease. To deliver this "instruction manual" into cells, they encapsulated it in Lipid Nanoparticles (LNPs) using the SM-102 ionizable lipid, the same technology used in modern mRNA vaccines.
To understand how the protease kills cancer, they used Mass Spectrometry (co-IP-MS) and cleavage site prediction to identify which human proteins the viral enzyme was targeting. They validated their findings across several platforms, including human cancer cell lines (glioblastoma, breast, liver) and mouse models. Safety controls compared the active 3C protease against a "dead" mutant version (C147S) to prove the killing effect was due to the enzyme's proteolytic activity.
Key Insights
- Target Identification: The 3C protease specifically targets hnRNP A1, a "master regulator" often overexpressed in cancers. When 3C protease shreds hnRNP A1, it disrupts the cell's ability to prevent apoptosis, specifically by activating the Apaf-1/Caspase-3 pathway.
- Immune-Independent Killing: Perhaps the most significant finding is that the therapy works even in "nude" mice (which lack T-cells) and in models where B-cells and NK cells were depleted. This confirms the therapy provides a direct kill-shot that doesn't require a functional immune system.
- Tumor Selectivity: Interestingly, the 3C-mRNA showed high toxicity toward cancer cells but was almost non-toxic to normal cells (like HUVECs). This suggests that cancer cells are uniquely "addicted" to the proteins the protease destroys.
- Anti-Angiogenesis: Beyond just killing cells, the 3C-LNPs were found to inhibit the growth of new blood vessels (angiogenesis) within the tumor, effectively starving the remaining cancer cells.
Key Results
In brain cancer models, intracranial injections of 3C-LNPs significantly inhibited tumor growth and dramatically prolonged survival compared to controls. In breast cancer models, local injections reduced tumor volume and weight significantly, with a clear dose-response relationship.
Furthermore, intravenous delivery (0.4 mg/kg) successfully targeted the liver, inhibited tumor growth, and extended survival in hepatocellular carcinoma models. Mice treated for up to 6 weeks showed no significant weight loss, no changes in liver enzymes (AST/ALT), and no histopathological damage to major organs like the heart, lungs, or kidneys, indicating a favorable safety profile.
Limitations and Future Work
While the results are striking, several hurdles remain for clinical translation:
- Delivery Logistics: While local injections (brain/breast) worked well, systemic (IV) delivery still primarily targets the liver. Developing LNPs that can home in on other specific organs or cross the blood-brain barrier remains a major challenge.
- Long-term Viral Protease Exposure: Although no acute toxicity was seen in mice, the long-term effects of expressing a viral protease in human tissues need rigorous clinical evaluation to ensure no "off-target" proteins are being slowly degraded in healthy cells.
- Clinical Translation: These studies were performed in mice. Human tumors are much more complex and heterogeneous, which may affect how well the 3C protease can penetrate and clear a large solid mass.
The study concludes that viral protease mRNA represents a promising "broad-spectrum" tool for the oncology cabinet, offering a way to bypass the limitations of current immunotherapies.
Summary updated